Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of General and Thoracic Surgery, Landeskrankenhaus Feldkirch, Feldkirch, Austria.
Tumori. 2023 Oct;109(5):450-457. doi: 10.1177/03008916231154763. Epub 2023 Feb 16.
Complex surgical resection and reconstruction for rare thoracic cancers (RTCs) represent a major challenge, given their very low frequency, extreme variability of presentation, multi-modality treatment options and inadequate outcome prediction. We analysed the experience of a tertiary referral centre on a consecutive series of patients with thoracic germ cell tumours, thymomas and sarcomas, with the aim of reporting the long-term outcome by cancer type and complexity of surgical procedures.
From Jan 2003 to Dec 2018, 768 surgical procedures were performed with curative intent on 644 RTC patients. Study endpoints were: post-operative hospital stay (Pod), 30-day and 90-day mortality, 5-year and 10-year overall survival (OS). Median follow-up of alive patients was 7.2 years.
Median Pod was 7 days, with a 1.2% 30-day and 2.9% 90-day mortality. OS was 90.8% at one year, 74.2% at five years and 62.8% at 10 years. Ten-year OS was 73.0% in low, 65.3% in intermediate, and 55.6% in high complexity score (Log-rank tests p<0.0001); 66.6% in patients with one or two reconstructions and 46.4% in patients with three or more reconstructions (p<0.0001); 46.0% with vascular and 50.0% with chest wall reconstruction; 71.8% in germ cell tumours, 64.6% in thymoma and 51.3% in sarcoma (p<0.0001).
Complex surgical resection and reconstruction was associated with acceptable 90-day mortality and good 10-year survival in all RTC types. A predictive score based on surgical complexity and cancer type can help the clinical decision making.
由于罕见的胸部癌症(RTC)的发病率非常低,表现形式多种多样,治疗方法多样,且预后预测不足,因此对其进行复杂的手术切除和重建是一项重大挑战。我们分析了一家三级转诊中心对一系列连续的胸生殖细胞瘤、胸腺瘤和肉瘤患者的治疗经验,旨在按癌症类型和手术复杂性报告长期结果。
从 2003 年 1 月至 2018 年 12 月,对 644 例 RTC 患者进行了 768 次以治愈为目的的手术。研究终点为:术后住院时间(Pod)、30 天和 90 天死亡率、5 年和 10 年总生存率(OS)。存活患者的中位随访时间为 7.2 年。
中位 Pod 为 7 天,30 天和 90 天死亡率分别为 1.2%和 2.9%。1 年 OS 为 90.8%,5 年 OS 为 74.2%,10 年 OS 为 62.8%。低复杂度评分的 10 年 OS 为 73.0%,中复杂度评分的为 65.3%,高复杂度评分的为 55.6%(对数秩检验 p<0.0001);1 次或 2 次重建的患者 10 年 OS 为 66.6%,3 次或更多重建的患者为 46.4%(p<0.0001);血管和胸壁重建的患者分别为 46.0%和 50.0%;生殖细胞瘤患者的 10 年 OS 为 71.8%,胸腺瘤患者为 64.6%,肉瘤患者为 51.3%(p<0.0001)。
在所有 RTC 类型中,复杂的手术切除和重建与可接受的 90 天死亡率和良好的 10 年生存率相关。基于手术复杂性和癌症类型的预测评分有助于临床决策。